Terns (TERN) | Financial Analysis & Statements
Terns Pharmaceuticals Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-27.6M
Net Income
-23.6M
Balance Sheet Metrics
Total Assets
1.0B
Total Liabilities
18.6M
Shareholders Equity
1.0B
Debt to Equity
0.02
Cash Flow Metrics
Operating Cash Flow
-21.1M
Free Cash Flow
-19.1M
Revenue & Profitability Trend
Terns Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1.0M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 77.9M | 70.1M | 63.5M | 39.6M | 31.3M |
| Selling, General & Administrative | 32.2M | 31.8M | 39.1M | 22.4M | 19.5M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 110.1M | 101.9M | 102.6M | 62.0M | 50.9M |
| Operating Income | -110.1M | -101.9M | -102.6M | -62.0M | -49.9M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | -4,986.0% |
| Non-Operating Items | |||||
| Interest Income | 14.6M | 13.3M | 12.9M | 2.1M | 170.0K |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | -93.0K | -11.0K | -314.0K | -68.0K | 40.0K |
| Pre-tax Income | -95.6M | -88.6M | -90.0M | -60.0M | -49.6M |
| Income Tax | 581.0K | 260.0K | 239.0K | 358.0K | 508.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -96.2M | -88.9M | -90.2M | -60.3M | -50.2M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | -5,015.8% |
| Key Metrics | |||||
| EBITDA | -109.6M | -101.0M | -101.7M | -61.0M | -49.3M |
| EPS (Basic) | - | $-1.12 | $-1.27 | $-1.67 | $-2.21 |
| EPS (Diluted) | - | $-1.12 | $-1.27 | $-1.67 | $-2.21 |
| Basic Shares Outstanding | - | 79507474 | 71259239 | 36033045 | 22705948 |
| Diluted Shares Outstanding | - | 79507474 | 71259239 | 36033045 | 22705948 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Terns Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 524.7M | 161.4M | 79.9M | 143.2M | 47.7M |
| Short-term Investments | 494.2M | 196.7M | 183.5M | 139.9M | 118.3M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 5.2M | 3.9M | 4.0M | 2.1M | 948.0K |
| Total Current Assets | 1.0B | 362.1M | 267.4M | 285.2M | 166.9M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 747.0K | 770.0K | 758.0K | 718.0K |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | 350.0K | 56.0K | 37.0K | 94.0K |
| Total Non-Current Assets | 884.0K | 1.8M | 1.1M | 1.8M | 1.1M |
| Total Assets | 1.0B | 363.9M | 268.5M | 287.0M | 168.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.7M | 2.1M | 2.5M | 1.6M | 2.1M |
| Short-term Debt | 474.0K | 428.0K | 603.0K | 661.0K | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 449.0K | 455.0K | 278.0K | 185.0K | 358.0K |
| Total Current Liabilities | 16.4M | 15.6M | 11.9M | 8.5M | 6.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 445.0K | 919.0K | 0 | 544.0K | 0 |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 2.1M | 2.4M | 1.2M | 1.6M | 947.0K |
| Total Liabilities | 18.6M | 18.1M | 13.2M | 10.1M | 7.8M |
| Equity | |||||
| Common Stock | 11.0K | 9.0K | 6.0K | 5.0K | 3.0K |
| Retained Earnings | -517.7M | -421.5M | -332.6M | -242.4M | -182.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.0B | 345.9M | 255.4M | 276.9M | 160.3M |
| Key Metrics | |||||
| Total Debt | 919.0K | 1.3M | 603.0K | 1.2M | 0 |
| Working Capital | 1.0B | 346.5M | 255.5M | 276.7M | 160.1M |
Balance Sheet Composition
Terns Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -96.2M | -88.9M | -90.2M | -60.3M | -50.2M |
| Depreciation & Amortization | 501.0K | 896.0K | 881.0K | 1.0M | 512.0K |
| Stock-Based Compensation | 13.4M | 15.6M | 25.5M | 10.8M | 8.1M |
| Working Capital Changes | -942.0K | -922.0K | 483.0K | -1.9M | 1.7M |
| Operating Cash Flow | -82.7M | -73.2M | -63.2M | -50.1M | -39.6M |
| Investing Activities | |||||
| Capital Expenditures | 0 | -42.0K | -52.0K | -275.0K | -340.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -405.0M | -169.9M | -275.8M | -139.7M | -166.3M |
| Investment Sales | 107.0M | 157.6M | 237.8M | 117.7M | 46.9M |
| Investing Cash Flow | -298.0M | -12.4M | -38.0M | -22.3M | -119.7M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | 0 |
| Debt Repayment | - | - | - | 0 | -12.9M |
| Financing Cash Flow | 706.2M | 161.9M | 41.3M | 166.9M | 133.5M |
| Free Cash Flow | -82.2M | -70.1M | -67.4M | -49.4M | -42.2M |
| Net Change in Cash | 325.4M | 76.3M | -59.9M | 94.5M | -25.8M |
Cash Flow Trend
Terns Key Financial Ratios
Valuation Ratios
Forward P/E
-35.92
Price to Book
5.90
PEG Ratio
-35.92
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-14.23%
Return on Assets
-9.91%
Financial Health
Current Ratio
62.41
Debt to Equity
0.09
Beta
-0.38
Per Share Data
EPS (TTM)
$-1.03
Book Value per Share
$8.96
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| TERN | 6.1B | - | 5.90 | -14.23% | 0.00% | 0.09 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






